Sickle Cell Disease Clinical Trial
Official title:
The Effects of Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya: a Pilot Study
Verified date | September 2017 |
Source | Kenya Medical Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Zinc is a nutritionally essential trace element found in previous studies to reduce growth retardation and improve immune function, which may also result in decreased incidence of infectious diseases including malaria, pneumonia and diarrhea. Sickle Cell Disease (SCD) patients are known to be susceptible to zinc deficiency and appear to benefit from zinc supplementation. The proposed pilot research project aims to investigate the influence of zinc supplementation on incidence of malaria infections, incidence of bacterial infections and investigate the influence of zinc supplementation on morbidity in children with SCD in western Kenya. The differences in incidence of morbidity and other secondary endpoints will be compared between the zinc group and the control group.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 19, 2017 |
Est. primary completion date | January 19, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 12 Years |
Eligibility |
Inclusion Criteria: - Male or female infants and children = 6 months and < 13 years of age with confirmed SCD. - Written informed consent obtained from the participant's parent/Legally Acceptable Representative (LAR). - Available to participate for the study duration (approximately six months) Exclusion Criteria: - Written informed consent NOT obtained from the participant's parent/Legally Acceptable Representative (LAR). - Profound clinical evidence of current immunosuppression or evidence of active AIDS defining illness i.e. WHO HIV clinical stage III/IV - History of allergic reactions to zinc or any other ingredients in the supplement - History of any neurologic disorders or seizures - Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, renal functional abnormality, as determined by physical examination or laboratory screening tests - Hemoglobin =7.0 g/dL in children aged 6 months to = 2 years. - Hemoglobin = 6 g/dL in children aged >2yrs to <13 years. - Total White Cell Count below normal range <4.5 x 103/uL - Use of any investigational or non-registered drugs or vaccines or planned use - Simultaneous participation in any other clinical trial - Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lucas Otieno Tina, MD MSc | GlaxoSmithKline, Strathmore University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of change in zinc levels from baseline at study conclusion. | Zinc Levels in Plasma | 6 months | |
Secondary | Number of malaria episodes among recipients of zinc versus controls diagnosed by RDT or Microscopy. | Malaria Incidence | 6 months | |
Secondary | Number of episodes of bacterial infections among recipients of zinc versus controls diagnosed by culture. | Bacterial Infection Incidence | 6 months | |
Secondary | Incidence of malnutrition among recipients of zinc versus controls diagnosed based on anthropometric measurements. | Anthropometric Measurements i.e. Weight, Height and Mid Upper Arm Circumference | 6 months | |
Secondary | Occurrences of Adverse Events (AEs) during the 6 month follow-up period among recipients of zinc versus controls. | Adverse Events including Serious Adverse Events | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 |